CHURCHILL CAPITAL CORP-CL A Share Price (NASDAQ: CCXI)

$10.19

▲

-0.01

(-0.1%)

Live

Last updated on February 27, 2026 at 12:37 am IST

$₹

Check the interactive CHURCHILL CAPITAL CORP-CL A Stock chart to analyse performance

CHURCHILL CAPITAL CORP-CL A Key Stats

Check CHURCHILL CAPITAL CORP-CL A key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$10.2
Market Capitalization	$3.7B
Revenue TTM	$37.3M
EBITDA	$-127.6M
Earnings Per Share (EPS)	$-2.0
Dividend Yield	0.0%
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-46.96%

Stock Returns calculator for CHURCHILL CAPITAL CORP-CL A Stock including INR - Dollar returns

The CHURCHILL CAPITAL CORP-CL A stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

CHURCHILL CAPITAL CORP-CL A investment value today

Current value as on today

₹1,00,000

Returns

₹0

(0%)

Returns from CHURCHILL CAPITAL CORP-CL A Stock

₹0 (0%)

Dollar Returns*

₹0 (0%)

Indian investors sentiment towards CHURCHILL CAPITAL CORP-CL A Stock

Period: Jan 31, 2026 to Mar 2, 2026. Change in 30 Days versus previous period

Search interest for CHURCHILL CAPITAL CORP-CL A Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in CHURCHILL CAPITAL CORP-CL A

Name
Holdings %
Name
Holdings %
FMR Inc
14.85%
Vanguard Group Inc
8.37%
Vanguard Group Inc
8.07%
Goldman Sachs Group Inc
7.81%
BlackRock Inc
6.74%
State Street Corporation
5.63%

Analyst Recommendation on CHURCHILL CAPITAL CORP-CL A Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for CHURCHILL CAPITAL CORP-CL A(by analysts ranked 0 to 5 stars)

CHURCHILL CAPITAL CORP-CL A Share Price Target

What analysts predicted

Upside of 410.3%

Target:

$52.00

Current:

$10.19

CHURCHILL CAPITAL CORP-CL A share price target is $52.00, a slight Upside of 410.3% compared to current price of $10.19 as per analysts' prediction.

CHURCHILL CAPITAL CORP-CL A Stock Insights

Price Movement
In the last 7 days, CCXI stock has moved up by 0.3%

CHURCHILL CAPITAL CORP-CL A Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY16

FY17

FY18

FY19

FY20

FY21

	FY16	Y/Y Change
Revenue	$11.4M	-
Net Income	$-40.0M	↓ 15.52%
Net Profit Margin	-349.48%	-

	FY17	Y/Y Change
Revenue	$82.5M	↑ 621.44%
Net Income	$17.9M	↓ 144.69%
Net Profit Margin	21.65%	↑ 371.13%

	FY18	Y/Y Change
Revenue	$42.9M	↓ 48.03%
Net Income	$-38.0M	↓ 312.59%
Net Profit Margin	-88.55%	↓ 110.2%

	FY19	Y/Y Change
Revenue	$36.0M	↓ 16.15%
Net Income	$-55.5M	↑ 46.15%
Net Profit Margin	-154.34%	↓ 65.79%

	FY20	Y/Y Change
Revenue	$64.9M	↑ 80.49%
Net Income	$-55.4M	↓ 0.24%
Net Profit Margin	-85.31%	↑ 69.03%

	FY21	Y/Y Change
Revenue	$32.2M	↓ 50.34%
Net Income	$-131.8M	↑ 138.01%
Net Profit Margin	-408.87%	↓ 323.56%

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

	Q1 FY21	Q/Q Change
Revenue	$10.2M	↑ 134.58%
Net Income	$-29.7M	↓ 0.55%
Net Profit Margin	-290.63%	↑ 394.91%

	Q2 FY21	Q/Q Change
Revenue	$1.7M	↓ 83.38%
Net Income	$-39.2M	↑ 31.97%
Net Profit Margin	-2.3K%	↓ 2017.14%

	Q3 FY21	Q/Q Change
Revenue	$17.7M	↑ 941.26%
Net Income	$-22.3M	↓ 43.11%
Net Profit Margin	-126.09%	↑ 2181.68%

	Q4 FY21	Q/Q Change
Revenue	$2.6M	↓ 85.24%
Net Income	$-40.5M	↑ 81.68%
Net Profit Margin	-1.6K%	↓ 1426.11%

	Q1 FY22	Q/Q Change
Revenue	$5.5M	↑ 109.08%
Net Income	$-38.6M	↓ 4.74%
Net Profit Margin	-707.24%	↑ 844.96%

	Q2 FY22	Q/Q Change
Revenue	$11.8M	↑ 115.48%
Net Income	$-31.7M	↓ 18.02%
Net Profit Margin	-269.07%	↑ 438.17%

FY16

FY17

FY18

FY19

FY20

FY21

	FY16	Y/Y Change
Profit	$11.9M	↓ 135.97%

	FY17	Y/Y Change
Profit	$82.5M	↑ 591.22%

	FY18	Y/Y Change
Profit	$42.9M	↓ 48.03%

	FY19	Y/Y Change
Profit	$36.1M	↓ 15.74%

	FY20	Y/Y Change
Profit	$64.9M	↑ 79.61%

	FY21	Y/Y Change
Profit	$31.9M	↓ 50.81%

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

	Q1 FY21	Q/Q Change
Profit	$10.2M	↑ 134.58%

	Q2 FY21	Q/Q Change
Profit	$1.8M	↓ 82.27%

	Q3 FY21	Q/Q Change
Profit	$17.7M	↑ 878.65%

	Q4 FY21	Q/Q Change
Profit	$2.3M	↓ 86.99%

	Q1 FY22	Q/Q Change
Profit	$5.3M	↑ 127.54%

	Q2 FY22	Q/Q Change
Profit	$11.0M	↑ 108.6%

FY16

FY17

FY18

FY19

FY20

FY21

	FY16	Y/Y Change
Operating Cash Flow	$39.1M	↓ 199.54%
Investing Cash Flow	$-48.8M	↓ 243.91%
Financing Cash Flow	$8.8M	↑ 302.56%

	FY17	Y/Y Change
Operating Cash Flow	$4.9M	↓ 87.54%
Investing Cash Flow	$15.6M	↓ 131.99%
Financing Cash Flow	$7.5M	↓ 14.78%

	FY18	Y/Y Change
Operating Cash Flow	$16.4M	↑ 236.94%
Investing Cash Flow	$-53.1M	↓ 440.14%
Financing Cash Flow	$24.7M	↑ 228.63%

	FY19	Y/Y Change
Operating Cash Flow	$-70.1M	↓ 526.64%
Investing Cash Flow	$-12.5M	↓ 76.4%
Financing Cash Flow	$94.8M	↑ 283.89%

	FY20	Y/Y Change
Operating Cash Flow	$-81.1M	↑ 15.72%
Investing Cash Flow	$-282.4M	↑ 2154.19%
Financing Cash Flow	$356.6M	↑ 276.1%

	FY21	Y/Y Change
Operating Cash Flow	$-75.6M	↓ 6.81%
Investing Cash Flow	$92.2M	↓ 132.66%
Financing Cash Flow	$1.1M	↓ 99.7%

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

	Q1 FY21	Q/Q Change
Operating Cash Flow	$-21.6M	↑ 12.19%
Investing Cash Flow	$60.7M	↓ 813.57%
Financing Cash Flow	$-2.9M	↓ 174.1%

	Q2 FY21	Q/Q Change
Operating Cash Flow	$-17.9M	↓ 17.23%
Investing Cash Flow	$25.8M	↓ 57.53%
Financing Cash Flow	$742.0K	↓ 126.04%

	Q3 FY21	Q/Q Change
Operating Cash Flow	$-25.3M	↑ 41.82%
Investing Cash Flow	$42.3M	↑ 64.27%
Financing Cash Flow	$-489.0K	↓ 165.9%

	Q4 FY21	Q/Q Change
Operating Cash Flow	$-10.9M	↓ 57.0%
Investing Cash Flow	$-36.5M	↓ 186.33%
Financing Cash Flow	$3.7M	↓ 852.56%

	Q1 FY22	Q/Q Change
Operating Cash Flow	$8.8M	↓ 181.12%
Investing Cash Flow	$-21.3M	↓ 41.61%
Financing Cash Flow	$3.1M	↓ 15.62%

	Q2 FY22	Q/Q Change
Operating Cash Flow	$-26.1M	↓ 395.84%
Investing Cash Flow	$28.1M	↓ 231.6%
Financing Cash Flow	$1.9M	↓ 39.94%

CHURCHILL CAPITAL CORP-CL A Technicals Summary

Sell

Neutral

Buy

CHURCHILL CAPITAL CORP-CL A is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

CHURCHILL CAPITAL CORP-CL A Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
CHURCHILL CAPITAL CORP-CL A	-0.88%	-0.88%	-0.88%	-0.88%	-82.22%
Regeneron Pharmaceuticals, Inc.	4.74%	36.84%	15.47%	1.34%	75.98%
Beone Medicines Ltd	-8.88%	-5.32%	28.03%	31.73%	8.69%
Vertex Pharmaceuticals Incorporated	2.97%	21.2%	0.56%	66.67%	133.9%
Alnylam Pharmaceuticals, Inc.	-4.14%	-27.28%	33.48%	62.78%	136.64%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
CHURCHILL CAPITAL CORP-CL A	NA	NA	0.0	-1.87	-0.47	-0.19	0.0	3.32
Regeneron Pharmaceuticals, Inc.	18.83	18.83	1.67	44.69	0.15	0.06	0.0	304.65
Beone Medicines Ltd	621.55	621.55	NA	5.59	0.07	0.04	NA	39.34
Vertex Pharmaceuticals Incorporated	32.47	32.47	2.58	19.16	0.23	0.12	NA	73.49
Alnylam Pharmaceuticals, Inc.	142.88	142.88	-0.49	9.56	0.73	0.07	NA	5.96

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
CHURCHILL CAPITAL CORP-CL A	Buy	$3.7B	-82.22%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$82.6B	75.98%	18.83	31.41%
Beone Medicines Ltd	NA	$35.1B	8.69%	621.55	5.37%
Vertex Pharmaceuticals Incorporated	Buy	$126.2B	133.9%	32.47	32.94%
Alnylam Pharmaceuticals, Inc.	Buy	$44.2B	136.64%	142.88	8.45%

CHURCHILL CAPITAL CORP-CL A Dividend announcements

CHURCHILL CAPITAL CORP-CL A Earnings
CHURCHILL CAPITAL CORP-CL A’s price-to-earnings ratio stands at None

About CHURCHILL CAPITAL CORP-CL A

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.

Organization	CHURCHILL CAPITAL CORP-CL A
Employees	178
CEO	Dr. Thomas J. Schall Ph.D.
Industry	Health Technology

Key Management of CHURCHILL CAPITAL CORP-CL A

Name	Title
Dr. Thomas J. Schall Ph.D.	Founder, Pres, CEO & Chairman
Ms. Susan M. Kanaya	Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
Mr. Tausif Butt	Exec. VP & COO
Dr. Rita I. Jain M.D.	Exec. VP, Chief Medical Officer & Exec. Employee Director
Dr. Markus J. Cappel Ph.D.	Chief Bus. Officer & Treasurer
Ms. Yi Ching Yau	Sr. VP of Fin. & Principal Accounting Officer
Mr. William S. Slattery	VP of Investor Relations & Corp. Communications
Ms. Kari E. Leetch	Sr. VP of HR
Dr. Sangita Ghosh Ph.D.	Sr. VP of Technical Operations

Important FAQs about investing in CCXI Stock from India :

What is CHURCHILL CAPITAL CORP-CL A share price today?

CHURCHILL CAPITAL CORP-CL A share price today is $10.19 as on February 27, 2026 at 12:37 am IST. CHURCHILL CAPITAL CORP-CL A share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for CHURCHILL CAPITAL CORP-CL A share?

CHURCHILL CAPITAL CORP-CL A share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. CHURCHILL CAPITAL CORP-CL A stock price today i.e. February 27, 2026 at 12:37 am IST is trending at $10.19, lower by 0% versus the 52 week high.

How to invest in CHURCHILL CAPITAL CORP-CL A Stock (CCXI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for CHURCHILL CAPITAL CORP-CL A on INDmoney app. Click on Buy button. You can invest as low as $1.5 in CHURCHILL CAPITAL CORP-CL A Shares that will get you 0.1472 shares as per CHURCHILL CAPITAL CORP-CL A share price of $10.19 per share as on February 27, 2026 at 12:37 am IST.

What is the minimum amount required to buy CHURCHILL CAPITAL CORP-CL A Stock (CCXI) from India?

Indian investors can start investing in CHURCHILL CAPITAL CORP-CL A (CCXI) shares with as little as ₹92.138 or $1 (as of March 03, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹921.38 in CHURCHILL CAPITAL CORP-CL A stock (as per the Rupee-Dollar exchange rate as on March 03, 2026). Based on CHURCHILL CAPITAL CORP-CL A share’s latest price of $10.19 as on February 27, 2026 at 12:37 am IST, you will get 0.9814 shares of CHURCHILL CAPITAL CORP-CL A. Learn more about fractional shares .

What are the returns that CHURCHILL CAPITAL CORP-CL A has given to Indian investors in the last 5 years?

CHURCHILL CAPITAL CORP-CL A stock has given -82.22% share price returns and 25.77% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?